Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia

Diabetes Research and Clinical Practice

Volumn 100, Issue 1, 2013, Pages

  Takemoto, Minoru ^a,b   Ishikawa, Takahiro ^a,b   Onishi, Shunichiro ^a,b   Okabe, Emiko ^a,b   Ishibashi, Ryoichi ^a,b   He, Peng ^a   Kobayashi, Kazuki ^a,b   Fujimoto, Masaki ^a,b   Kawamura, Harukiyo ^a,b   Yokote, Koutaro ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Atorvastatin; Diabetic nephropathy; Podocyte; Rosuvastatin; Statin; Urinary podocyte

Indexed keywords

ALBUMIN; ATORVASTATIN; ISOPROSTANE DERIVATIVE; ROSUVASTATIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PODOCYTE; PODOCYTE INJURY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY EXCRETION;

AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PODOCYTES; PYRROLES;

EID: 84876735502     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.12.018     Document Type: Article

References (16)

1. Sandhu S., Wiebe N., Fried L.F., Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006, 17:2006-2016.
2. Navaneethan S.D., Pansini F., Strippoli G.F. Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trials. PLoS Med 2006, 3:e123.
3. Navaneethan S.D., Pansini F., Perkovic V., Manno C., Pellegrini F., Johnson D.W., et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009, CD007784.
4. ClinicalTrials.gov.PLANETI: prospective evaluation of proteinuria and renal function in diabetic patients with progressive renal disease. [accessed 03.03.10]. http://clinicaltrials.gov/ct2/show/NCT00296374%3Fterm=planet%26rank=1.
5. Kriz W., Gretz N., Lemley K.V. Progression of glomerular diseases: is the podocyte the culprit?. Kidney Int 1998, 54:687-697.
6. Hara M., Yanagihara T., Takada T., Itoh M., Matsuno M., Yamamoto T., et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998, 18:35-41.
7. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Ebihara I., et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379-1383.
8. Wu Y., Wang Y., An C., Dong Z., Liu H., Zhang Y., et al. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Circ J 2012, 76:1259-1266.
9. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000, 20:175-179.
10. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Sekizuka K., et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000, 20:373-379.
11. Kihara I., Tsuchida S., Yaoita E., Yamamoto T., Hara M., Yanagihara T., et al. Podocyte detachment and epithelial cell reaction in focal segmental glomerulosclerosis with cellular variants. Kidney Int Suppl 1997, 63:S171-S176.
12. Shibata S., Nagase M., Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006, 17:754-764.
13. Mason R.P., Walter M.F., Day C.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005, 96:11F-23F.
14. Mason R.P., Walter M.F., Day C.A., Jacob R.F. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 2006, 281:9337-9345.
15. Golbidi S., Ebadi S.A., Laher I. Antioxidants in the treatment of diabetes. Curr Diabetes Rev 2011, 7:106-125.
16. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.